Wire · opportunities
FDA greenlights Revolution Medicines' pancreatic cancer gamechanger
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The FDA has approved Revolution Medicines' RAS inhibitor daraxonrasib, branded Rasonque, for metastatic pancreatic cancer, marking a significant breakthrough in treating this hard-to-treat cancer. The drug showed unprecedented clinical results, doubling overall and progression-free survival and improving quality of life, and the company aims to expand its use and advance other RAS inhibitors.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
Your pancreatic cancer treatment options just expanded with the first targeted RAS inhibitor approved by the FDA. You can now compete or collaborate in a market that turned from untreatable to addressable overnight.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics